RCKT Rocket Corp: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Rocket Pharmaceuticals (RCKT) specializes in developing innovative drugs for the treatment of severe genetic pathologies. This chart reflects the current market value on GURU.Markets at 0.00, confirming its status as a global innovator that enjoys deep trust from the medical community. The executive team demonstrates proficiency in navigating FDA approvals, confidently transitioning developments into the commercial stage. However, a lack of diversification and dependence on a narrow pipeline of drugs create high risks for investors.

This ratio determines the business value relative to its operating profit, accounting for debt load and tax obligations. For Rocket Pharmaceuticals (RCKT), which operates in the non-cyclical gene therapy sector, the EV/EBITDA multiple trend reflects market expectations regarding drug approvals. The current value of 0.00 serves as a risk premium indicator. The stability of this metric confirms the fundamental resilience of Rocket Pharmaceuticals regardless of macroeconomic fluctuations.